# Xenobiology & expanded genetic alphabet (XNA)

Orthogonal biological systems built on xeno-nucleic acids, unnatural base pairs and genomically recoded organisms that incorporate noncanonical amino acids into proteins — enabling site-specific drug conjugation and a genetic firewall against horizontal gene transfer with wild species.

Source: https://en.bioecon.ru/technology/xenobiology-expanded-genetic-alphabet/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: Orthogonal biosystems & biosecurity | OECD: Synthetic biology | Regulator: FDA (US), EPA (US), MOST (China)]

Xenobiology designs orthogonal biological systems chemically isolated from the natural biosphere — organisms built on xeno-nucleic acids (XNA), unnatural base pairs, or genomically recoded codons that incorporate noncanonical amino acids (ncAAs) into proteins. Sanofi's Synthorx platform, acquired for $2.5 billion, produces SAR-444245 (pegenzileukin, also called THOR-707), an engineered "not-alpha" IL-2 cytokine that uses site-specific PEGylation through an ncAA to eliminate the vascular-leak toxicity of classical IL-2; the PEGATHOR study (NCT05104567) reported results in June 2026 testing it in combination with pembrolizumab and other checkpoint inhibitors. Firebird Biomolecular Sciences, built on Steven Benner's Hachimoji (eight-letter) DNA system, contributed to a June 2026 Nature Communications study expanding triplex-forming oligonucleotide recognition of DNA using the expanded genetic alphabet (AEGIS), identifying modular base triads for programmable, sequence-specific applications. Scripps Research reported a March 2026 Nature Chemistry study on multi-type rare codon recoding that enables site-specific incorporation of up to five distinct ncAAs simultaneously in mammalian cells, alongside a separate reprogrammed genetic code expanding to 32 total amino acids. Yale University's Farren Isaacs lab unveiled "Ochre" in February 2025, a next-generation genomically recoded organism (GRO) that fully compresses redundant codons into a single stop codon, succeeding the earlier C321.ΔA strain and enabling programmable-protein production for therapeutic and industrial applications. KU Leuven's Rega Institute (Piet Herdewijn's group) published structural work on a Thermococcus kodakarensis DNA polymerase engineered for HNA (hexose nucleic acid) reverse transcription, providing the first structural insight into how a DNA polymerase processes a xeno-nucleic acid. In China, Peking University researchers Chen Peng and Yi Chengqi published a June 2025 codon-expansion strategy using post-transcriptionally modified RNA codons to incorporate ncAAs into mammalian cells without disturbing the natural genetic code.

The key directions of xenobiology and the expanded genetic alphabet are:
1. **Xeno-nucleic acids (XNA):** DNA-like polymers with the deoxyribose sugar replaced by alternative sugars (hexose/HNA, threose/TNA, glycerol/GNA, arabinose/ANA), giving near-total resistance to natural nucleases.
2. **Unnatural base pairs (UBPs):** artificial nucleotides that pair via mechanisms other than Watson-Crick hydrogen bonding, enabling semi-synthetic organisms that stably propagate a six- or eight-letter genetic code across hundreds of generations.
3. **Genetic code expansion via amber suppression:** reprogramming the amber (UAG) stop codon with an orthogonal tRNA/synthetase pair to insert a noncanonical amino acid at a precise protein position instead of terminating translation.
4. **Genomically recoded organisms (GROs):** removing a specific codon entirely from a genome (and its corresponding release factor), freeing that codon as a dedicated, collision-free channel for ncAA incorporation.

### Sectoral value chain

```
[Orthogonal pair design] ──> [Chemical synthesis of XNA/ncAA] ──> [Genomically recoded organism (GRO) assembly]
                                                                          │
                                                               (Amber-suppression translation)
                                                                          │
          [Therapeutic XNA aptamers] <─── [Click-chemistry ADC conjugation] <─── [ncAA-protein isolation]
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Orthogonal design** | Computational modeling of non-biological nucleotide pairs and the 3D structure of orthogonal tRNA/synthetase pairs. | **In:** Protein crystallography data, quantum-chemistry and docking software.<br>**Out:** Molecular specifications for UBP structures and enzyme active sites. |
| **XNA/ncAA synthesis** | De novo chemical synthesis of high-purity unnatural nucleoside triphosphates (dNTPs) and noncanonical amino acids. | **In:** Chemical precursors, organic-synthesis reagents.<br>**Out:** Crystalline ncAAs and solutions of orthogonal dNTPs. |
| **Genome recoding (GRO assembly)** | De novo construction of chromosomes with target codons replaced and the corresponding release-factor gene knocked out. | **In:** Multiplex CRISPR cassettes, MAGE/CAGE systems, wild-type bacteria.<br>**Out:** Stable genomically recoded host strain (GRO). |
| **Suppression translation (fermentation)** | Culturing the GRO strain in the presence of an ncAA to express proteins with site-specific incorporation of the artificial amino acid. | **In:** GRO bacteria, fermenters, mineral media, ncAA supplements.<br>**Out:** Crude recombinant protein bearing an orthogonal reactive tag. |
| **Click conjugation** | Chemically joining the purified protein to a payload molecule (PEG, toxin) via copper-free click chemistry (SPAAC). | **In:** ncAA-protein, click linkers bearing toxin/PEG, catalysts.<br>**Out:** Homogeneous, high-purity antibody-drug conjugate with a fixed drug-to-protein ratio. |
| **XNA application** | Directed evolution (SELEX) of xeno-nucleic acids to generate stable therapeutic aptamers and molecular sensors. | **In:** XNA libraries, evolved polymerases, target molecules.<br>**Out:** Stable, injectable XNA-based therapeutics. |

Cross-cutting technologies of the sector:
- **Compartmentalized self-replication (CSR):** directed in vitro evolution of polymerases inside water-in-oil emulsion droplets, each containing a single cell with a mutant polymerase gene and XNA substrates, selecting for enzymes able to synthesize genes using an artificial nucleic-acid backbone.
- **Copper-free click chemistry (SPAAC):** a highly selective reaction between azide and cyclooctyne (DBCO) groups integrated into noncanonical amino acids, proceeding under physiological conditions without toxic copper catalysts, essential for injectable-drug manufacturing.
- **Multiplex Automated Genome Engineering (MAGE):** cyclic introduction of dozens of single-stranded DNA oligonucleotides into dividing bacterial cells via lambda-Red recombination proteins, enabling rapid replacement of hundreds of codons genome-wide within days.

---

## US

The United States leads global commercialization of xenobiology-derived drugs and genomically recoded strains, anchored by Scripps, Yale and major pharmaceutical acquisitions.

### Sanofi's commercial Synthorx platform, Firebird's expanded-alphabet diagnostics, Scripps' multi-ncAA recoding, Yale's next-gen "Ochre" GRO
- **Sanofi (Synthorx):** its SAR-444245 (pegenzileukin/THOR-707), an engineered IL-2 cytokine using site-specific PEGylation through an ncAA, reported PEGATHOR (NCT05104567) combination results with pembrolizumab in June 2026, eliminating the vascular-leak toxicity that limited classical IL-2 therapy.
- **Firebird Biomolecular Sciences:** built on Steven Benner's Hachimoji eight-letter DNA/RNA system, contributed to a June 2026 Nature Communications study expanding triplex-forming oligonucleotide DNA recognition using the expanded genetic alphabet (AEGIS) for programmable, sequence-specific applications.
- **Scripps Research and Yale University:** Scripps reported a March 2026 multi-type rare codon recoding system enabling simultaneous site-specific incorporation of up to five distinct ncAAs in mammalian cells; Yale's Farren Isaacs lab unveiled "Ochre" in February 2025, a next-generation genomically recoded organism succeeding the earlier C321.ΔA strain.

---

## CN

China is building genetic-code-expansion capability through university chemistry and life-sciences labs, targeting mammalian-cell applications for biomedical research and diagnostics.

### Peking University's mammalian codon-expansion strategy, national grant-funded synthetic genetics programs
- **Peking University:** researchers Chen Peng (College of Chemistry and Molecular Engineering) and Yi Chengqi (School of Life Sciences) published a June 2025 codon-expansion strategy using post-transcriptionally modified RNA codons — distinct from all 64 standard codons — to incorporate ncAAs into mammalian systems without disturbing the natural genetic code.
- **National grant funding:** China's genetic-code-expansion and synthetic-genetics research is substantially funded through National Natural Science Foundation of China (NSFC) grants supporting university chemistry and life-sciences departments.
- **Application focus:** Chinese groups working in this Industry emphasize mammalian-cell-compatible codon expansion for biomedical protein engineering rather than the bacterial genomically recoded organisms that dominate the US commercial pipeline.

---

## EU

The European Union leads xeno-nucleic-acid chemistry and alternative sugar-phosphate backbone engineering, anchored by KU Leuven's structural biology of XNA polymerases.

### KU Leuven's HNA polymerase structural biology, Rega Institute's XNA synthesis leadership
- **KU Leuven (Rega Institute):** Piet Herdewijn's group published structural work on a Thermococcus kodakarensis DNA polymerase (KOD-H4) engineered for HNA (hexose nucleic acid) reverse transcription, providing the first structural insight into how a DNA polymerase processes a xeno-nucleic acid backbone.
- **XNA chemistry leadership:** KU Leuven remains a leading academic center for the chemical synthesis of hexose nucleic acids and related xeno-nucleic-acid backbones, building the structural foundation for stable, nuclease-resistant XNA aptamers and diagnostic sensors.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Sanofi (Synthorx)** | 🇫🇷 France | *SAR-444245* (pegenzileukin/THOR-707) | Semi-synthetic organism with ncAA-based site-specific PEGylation | operating |
| **Firebird Biomolecular Sciences** | 🇺🇸 USA | Hachimoji DNA, AEGIS expanded alphabet | Eight-letter genetic alphabet for ultra-sensitive diagnostics | operating |
| **Scripps Research Institute** | 🇺🇸 USA | Multi-type rare codon recoding | Simultaneous incorporation of up to 5 distinct ncAAs | research |
| **Yale University (Isaacs Lab)** | 🇺🇸 USA | "Ochre" genomically recoded organism | Next-gen GRO succeeding C321.ΔA, single dedicated stop codon | research |
| **KU Leuven (Rega Institute)** | 🇧🇪 Belgium | HNA/XNA polymerase engineering | First structural map of DNA polymerase processing HNA | research |
| **Peking University** | 🇨🇳 China | Mammalian codon-expansion strategy | Post-transcriptionally modified RNA codons for ncAA incorporation | research |

---

## Tech stack and innovations

The xenobiology stack layers three distinct orthogonal-biology approaches, each solving a different piece of the genetic-code-expansion problem:

1. **Semi-synthetic organisms (SSOs):**
   - Bacteria carrying artificial base pairs (such as d5SICS-dNaM) held together by hydrophobic interactions rather than hydrogen bonds; because the cell cannot synthesize the unnatural nucleoside triphosphates itself, a nucleotide-transporter gene from diatoms (PtNTT2) is engineered into its membrane so it imports the artificial nucleotides supplied in growth media, enabling stable propagation of a six- or eight-letter genetic code.
2. **Amber codon suppression:**
   - An orthogonal aminoacyl-tRNA synthetase/tRNA pair, typically sourced from a different domain of life (e.g., archaeal Methanosarcina barkeri) to avoid cross-reactivity with the host's native tRNAs, recognizes the reprogrammed UAG stop codon and inserts a noncanonical amino acid into the growing peptide chain instead of terminating translation.
3. **Genomically recoded organisms (GROs):**
   - Every instance of a target codon (e.g., UAG) is replaced genome-wide with a synonymous codon, then the gene encoding the corresponding release factor is deleted, freeing that codon as a collision-free channel that can encode any of 100+ noncanonical amino acids at near-100% efficiency.

---

## Value chains and production pipelines

### Industrial pipeline for a site-specifically PEGylated IL-2 immunocytokine conjugate via amber-suppression translation in a GRO E. coli strain with copper-free click conjugation

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Computational design of │ ───> │ 2. Synthesis of orthogonal │
│    the ncAA insertion site     │      │    reagents (pAzF, aaRS)       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Isolation of purified   │ <─── │ 3. GRO fermentation with   │
│    azido-protein IL-2-N3       │      │    amber suppression            │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. SPAAC click conjugation │ ───> │ 6. GMP purification, QC    │
│    with PEG-DBCO linker        │      │    and fill-finish              │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Computational design of the ncAA insertion site
Protein-engineering software identifies a surface-exposed, non-catalytic position on the target protein (e.g., IL-2) suitable for site-specific ncAA incorporation without disrupting receptor-binding activity.

#### Stage 2: Synthesis of orthogonal reagents
Para-azidophenylalanine (pAzF) or a similar clickable noncanonical amino acid is synthesized alongside its cognate orthogonal aminoacyl-tRNA synthetase, engineered to charge only the intended tRNA with this specific ncAA.

#### Stage 3: GRO fermentation with amber suppression
A genomically recoded E. coli strain is fermented in the presence of the ncAA; the orthogonal tRNA/synthetase pair inserts the ncAA at the reprogrammed codon position, producing a crude protein bearing a single, precisely positioned clickable handle.

#### Stage 4: Isolation of purified azido-protein
The azide-tagged protein is purified from the fermentation broth using standard chromatography, yielding a homogeneous preparation with the reactive group exposed at one defined site.

#### Stage 5: SPAAC click conjugation with PEG-DBCO linker
The purified protein is reacted with a DBCO-functionalized PEG or drug-linker molecule via strain-promoted azide-alkyne cycloaddition, forming a stable triazole linkage without any toxic copper catalyst, at a fixed one-to-one conjugation ratio.

#### Stage 6: GMP purification, QC and fill-finish
The conjugate undergoes final GMP-grade purification and quality-control testing to confirm conjugation homogeneity and purity, before aseptic fill-finish into vials for clinical or commercial distribution.